Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan, Huocong Huang, J. Scott Sawyer, Jeremy Graff, David K. Clawson, Karen S. Britt, Bryan D. Anderson, Douglas W. Beight, Durisala Desaiah, Michael M. Lahn, Karim A. Benhadji, Maria J. Lallena, Rikke B. Holmgaard, Xiaohong Xu, Faming Zhang, Jason R. Manro, Philip W. Iversen, Chandrasekar V. IyerRolf A. Brekken, Michael D. Kalos, Kyla E. Driscoll

Pharmacology
Surgical Oncology
Surgery

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Sort by
Weight
Alphabetically

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Fingerprint

Medicine & Life Sciences